KEPHERA DIAGNOSTICS LLC
- FRAMINGHAM, MA 01702-6767
- kephera.com (company website, opens in a new tab)
- Other
- SAM active
- No verified credentials yet
- CMMCNot on file
- SPRSNone
- FCLVisible to paid members
- Small Business
Registration and small-business types: SAM.gov, synced Nov 9, 2026. Compliance: self-attested by the company unless marked verified. The SPRS chip shows a range, never the exact score. How verification works
- 36-mo obligations
- $0
- Awards on record
- 0
- Contract vehicles
- 0
- Verified credentials
- 0
Compliance posture: unverified (SAM.gov baseline only)
KEPHERA DIAGNOSTICS LLC has not claimed this profile. What you see comes from public SAM.gov and USAspending records; no one from the company has confirmed CMMC, SPRS or clearance details yet. Learn more about CMMC 2.0
About KEPHERA DIAGNOSTICS LLC
- Headquarters
- FRAMINGHAM, MA 01702-6767
Identifiers
UEI and CAGE come from SAM.gov. Other identifiers are listed by the company.
- UEILJFNSE6NM648
- CAGE7RVB8
Capabilities & differentiators
No capability narrative yet
Compliance posture
No compliance posture published yet
Facility clearance
Facility clearance: visible to paid members
Clearance levels are shown only to paying members; TeamingIndex does not advertise clearances (NISPOM 32 CFR 117.9). Learn more about facility clearances · Compare plans
Past performance
No federal prime awards on record
Contract vehicles
No contract vehicles on file
Proven teaming graph
No sub-award reports yet
Source: USAspending.gov sub-award reports (FSRS) (opens in a new tab) · sync date not recorded · Prime contractors report first-tier subcontracts of $30,000 or more. Amounts are reported sub-award values.
SBIR/STTR portfolio
SBIR/STTR awardee — Phase III-eligible for work derived from its SBIR/STTR projects
Agencies may award follow-on Phase III work without a new competition when it builds on this company’s earlier SBIR/STTR projects. Other work is competed as usual.
- Awards on record
- 19 awards
- Total awarded
- $22,272,846
- By phase
- SBIR Phase I: 12
- SBIR Phase II: 7
- By agency
- Department of Health and Human Services: 19
- Active projects
- 1 project
- Projects whose contract end date is today or later.
- Phase II ending within 12 months
- 0 projects
- Phase II projects ending within 12 months. Agencies may award Phase III work without a new competition only when it derives from, extends or completes these projects.
- By year
- 2025: 2
- 2024: 3
- 2023: 5
- 2021: 2
- 2020: 2
- 2019: 2
- 2018: 2
- 2017: 1
Awards (most recent first)
Peptide-based ELISA for laboratory diagnosis of sarcoidosis
SBIR Phase II · Department of Health and Human Services (National Institutes of Health) · 2025 · $978,191
Sep 15, 2025 – Aug 31, 2028
- Active
Solicitation PA24-245 (2024) · Topic NHLBI
Novel Diagnostic Biomarker Discovery and Validation for Malaria
SBIR Phase I · Department of Health and Human Services (National Institutes of Health) · 2025 · $300,000
Solicitation PHS 2024-1 (2023) · Topic 132
MiCRIA: Two-minute rapid assay platform for point-of-care diagnosis
SBIR Phase I · Department of Health and Human Services (Centers for Disease Control and Prevention) · 2024 · $303,250
Sep 30, 2024 – Mar 31, 2025
Solicitation PA23-230 (2023) · Topic GHC
Diagnostic assay for congenital Chagas disease
SBIR Phase I · Department of Health and Human Services (National Institutes of Health) · 2024 · $606,500
May 1, 2024 – Apr 30, 2026
Solicitation PA23-230 (2023) · Topic NIAID
SBIR Topic 133: Development of a Serological Test for Herpes Simplex Types 1 and 2 Infections
SBIR Phase I · Department of Health and Human Services (National Institutes of Health) · 2024 · $300,000
Solicitation PHS-2024-1 (2024) · Topic 133
Hybrid ELISA: Simple and specific one-tier assay for Lyme disease
SBIR Phase II · Department of Health and Human Services (National Institutes of Health) · 2023 · $2,764,666
Sep 11, 2023 – Aug 31, 2026
Solicitation PA22-176 (2022) · Topic R44
Biomarker-Based Test of Cure for Chagas Disease
SBIR Phase II · Department of Health and Human Services (National Institutes of Health) · 2023 · $2,934,864
Sep 5, 2023 – Aug 31, 2026
Solicitation PA22-176 (2022) · Topic NIAID
Rapid Point-of-Care Assay for Diagnosis of Neurocysticercosis in Seizure Patients
SBIR Phase II · Department of Health and Human Services (National Institutes of Health) · 2023 · $2,999,008
May 12, 2023 – Apr 30, 2026
Solicitation PA22-176 (2022) · Topic NIAID
Development of an ELISA for serosurveillance of human hookworm
SBIR Phase I · Department of Health and Human Services (National Institutes of Health) · 2023 · $600,000
Apr 1, 2023 – Mar 31, 2025
Solicitation PA22-176 (2022) · Topic NIAID
Point-of-care diagnostic test for T. cruzi (Chagas) infection
SBIR Phase II · Department of Health and Human Services (National Institutes of Health) · 2023 · $3,050,000
Apr 1, 2023 – Mar 31, 2026
Solicitation PA21-259 (2021) · Topic NIAID
TOPIC 388: IN VITRO DIAGNOSTIC FOR THE LIVER FLUKES OPISTHORCHIS VIVERRINI AND CLONORCHIS SINENSI
SBIR Phase II · Department of Health and Human Services (National Institutes of Health) · 2021 · $1,999,961
Solicitation PHS2019-1 (2018) · Topic 388
DEVELOP A BIOMARKER-BASED TEST OF CURE (TOC) TO EVALUATE TREATMENT OUTCOME DURING THE CHRONIC PHASE OF CHAGAS INFECTION.
SBIR Phase I · Department of Health and Human Services (National Institutes of Health) · 2021 · $300,000
Solicitation PHS2021-1 (2020) · Topic 96
Serologic assays for detection of Zika virus antibodies for clinical diagnosis and blood donor counseling
SBIR Phase II · Department of Health and Human Services (National Institutes of Health) · 2020 · $1,989,300
Jul 22, 2020 – Jun 30, 2022
Solicitation PA19-272 (2019) · Topic NIAID
Rapid Point-of-Care Assay for Diagnosis of Neurocysticercosis in Seizure Patients
SBIR Phase I · Department of Health and Human Services (National Institutes of Health) · 2020 · $599,996
Jan 10, 2020 – Dec 31, 2021
Solicitation PA18-574 (2018) · Topic NIAID
Biomarker-Based Test of Cure for Chagas Disease
SBIR Phase I · Department of Health and Human Services (National Institutes of Health) · 2019 · $600,000
Jul 16, 2019 – Jun 30, 2021
Solicitation PA18-574 (2018) · Topic NIAID
Hybrid ELISA: Simple and specific one-tier assay for Lyme disease
SBIR Phase I · Department of Health and Human Services (National Institutes of Health) · 2019 · $599,658
Mar 6, 2019 – Feb 28, 2021
Solicitation PA18-574 (2018) · Topic NIAID
Point-of-care diagnostic test for T. cruzi (Chagas) infection
SBIR Phase I · Department of Health and Human Services (National Institutes of Health) · 2018 · $599,316
Aug 7, 2018 – Jul 31, 2020
Solicitation PA16-302 (2016) · Topic NIAID
Development of Rapid Antigen Detection Assays For Taeniasis
SBIR Phase I · Department of Health and Human Services (Centers for Disease Control and Prevention) · 2018 · $150,000
Solicitation year 2018 · Topic ODCDC
Serologic assays for detection of Zika virus antibodies for clinical diagnosis and blood donor counseling
SBIR Phase I · Department of Health and Human Services (National Institutes of Health) · 2017 · $598,136
Aug 18, 2017 – Jul 31, 2019
Solicitation PA16-302 (2016) · Topic NIAID
Source: SBIR.gov award data file (opens in a new tab) · as of Nov 12, 2026 · file published Nov 1, 2026
FedRAMP offerings
No FedRAMP Marketplace listing
Source: FedRAMP Marketplace (opens in a new tab) · sync date not recorded
Exclusions & screening
SAM.gov exclusions
Not yet checked against SAM.gov exclusions.
Agencies generally may not award to excluded parties, and primes may not subcontract with them above the threshold in FAR 52.209-6 (except COTS items) without a compelling reason reported to the contracting officer (FAR 9.405, 9.405-2). Some exclusion types apply only to specific programs: read the record on SAM.gov.
Source: SAM.gov Exclusions (opens in a new tab) · sync date not recorded
Consolidated Screening List
No confirmed match on the Consolidated Screening List (screened Nov 13, 2026).
The list combines Commerce, State and Treasury export-control and sanctions lists. A “no match” result is a name-and-address screen, not an export-compliance determination.
Source: ITA Consolidated Screening List (opens in a new tab) · as of Nov 13, 2026
GSA CALC+ rate benchmark
No GSA CALC+ rates on record
Source: GSA CALC+ awarded ceiling rates (opens in a new tab) · sync date not recorded
NAICS, PSC & socio-economic status
NAICS codes
- 325413Title not in the curated listPrimarySmall business under this code’s size standard
- 541714Research and Development in Biotechnology (except Nanobiotechnology)Small business under this code’s size standard
SAM.gov reports this entity as small under 2 of 2 NAICS codes. Size is determined per code (SBA size standards).
Product & service codes (PSC)
- 6550IN VITRO DIAGNOSTIC SUBSTANCES, REAGENTS, TEST KITS AND SETS
PSC names from the Acquisition.gov PSC Manual (opens in a new tab) (April 2025 edition), checked Nov 12, 2026.
Teaming preferences
This company has not published teaming preferences.
Business development contact
No BD contact published
Corporate hierarchy
No parent entity reported in SAM.gov.
SBA counts affiliates when it determines whether a business is small (13 CFR 121.103), so a parent’s size can matter for set-aside work.
Data sources & provenance
SAM.gov
Registration, CAGE, NAICS, socio-economic status, corporate hierarchy and exclusions. Last synced Nov 9, 2026.
USAspending.gov
Prime award history and obligations (FPDS), synced nightly.
The contractor
Nothing yet: this profile has not been claimed by the company.
TeamingIndex verification
Credentials marked Verified were checked by a TeamingIndex reviewer; everything else is self-attested.
Corrections
Corrections to SAM.gov data must be made in SAM.gov; TeamingIndex picks them up on the next nightly sync. Go to SAM.gov (opens in a new tab)
Machine-readable: capability.md schema.org JSON-LD embedded in this page.
Zero CUI: TeamingIndex stores verification metadata only, never System Security Plans, POA&Ms or DD Form 254s.
Teaming
Ready to team with KEPHERA DIAGNOSTICS LLC?
Send an introduction and propose a mutual NDA. Their team is notified right away, and you can share the capability statement with your capture team.
